Home › Therapeutic areas › Neurology › Myasthenia Gravis
Myasthenia Gravis (8 companies)
Companies with an active program in Myasthenia Gravis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 1 | 8 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | 4 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 1 | Phase 3 | 6 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | 7 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | 8 |
| TGTX | Tg Therapeutics | Neurology Rare | 2 | Approved | 6 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | 1 | Phase 3 | 2 |
| XNCR | Xencor | HematologyImmunology+4 Rare | 1 | Approved | 36 |
No companies match.